Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Psychosis and Antipsychotic Drugs: Overview01:28

Psychosis and Antipsychotic Drugs: Overview

414
The term "psychosis" refers to a spectrum of mental disorders characterized by abnormal thoughts, perceptions, and behaviors. It can manifest as mood disorders, dementia, delirium with psychotic features, substance-induced psychosis with psychotic features, brief psychotic disorder, delusional disorder, schizoaffective disorder, and schizophrenia. Among all these disorders, schizophrenia is the most common psychotic disorder, affecting 1% of the worldwide population. Psychotic...
414
Hallucinogens and Psychedelics01:27

Hallucinogens and Psychedelics

252
Hallucinogens are psychoactive substances that profoundly alter perceptual experiences, generating unreal visual and sensory images. Often referred to as psychedelic drugs — a term derived from the Greek words "psyche" (mind) and "delos" (revealing) — these substances include marijuana and lysergic acid diethylamide (LSD), among others. These drugs vary in intensity and effects.
Marijuana, derived from the dried leaves and flowers of the hemp plant, contains...
252
Psychosis: Pathophysiology of Schizophrenia and Other Psychotic Disorders01:27

Psychosis: Pathophysiology of Schizophrenia and Other Psychotic Disorders

871
Schizophrenia is a neurodevelopmental disorder whose origins are rooted in complex genetic components. Despite our burgeoning understanding, the pathophysiology of this disorder remains incompletely deciphered.
Researchers have identified genetic factors that increase susceptibility to schizophrenia, underscoring the intricate interplay between genetics and environment in disease development. At the core of schizophrenia's pathophysiology is excessive dopaminergic neurotransmission within...
871
Psychosis: Goals of Pharmacotherapy01:26

Psychosis: Goals of Pharmacotherapy

185
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
185
Psychological and Sociocultural Causes of Schizophrenia01:29

Psychological and Sociocultural Causes of Schizophrenia

165
Schizophrenia, a complex psychiatric disorder, has been historically misunderstood. Early psychological theories attributed its origins to childhood trauma and unresponsive parenting. However, contemporary research largely rejects these notions, favoring the vulnerability-stress hypothesis. This model proposes that individuals with a genetic predisposition to schizophrenia may develop the disorder following exposure to significant environmental stressors. Notably, studies on high-risk...
165
Chemotherapy-Induced Nausea and Vomiting: Cannabinoids01:21

Chemotherapy-Induced Nausea and Vomiting: Cannabinoids

359
Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...
359

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Enhancing Role Functioning in Clinical High Risk for Psychosis: An Open Trial of "InVEST" (Individualised Vocational and Educational Support and Training).

Early intervention in psychiatry·2025
Same author

Clinical High Risk for Psychosis in Sexual and Gender Minority Populations: Considerations for Assessment and Treatment.

Journal of the American Academy of Child and Adolescent Psychiatry·2025
Same author

Prevalence and Clinical Correlates of Suicidal Ideation and Attempts in Individuals at Clinical High Risk for Psychosis.

Early intervention in psychiatry·2024
Same author

Extortion experiences of recent adult immigrants from Latin America: self-reported prevalence, associated costs, and current mental health.

Injury epidemiology·2024
Same author

Overlap of obsessive compulsive and psychosis risk symptoms in a specialized clinic.

Early intervention in psychiatry·2024
Same author

Cannabis and Psychosis.

The Psychiatric clinics of North America·2023

Related Experiment Video

Updated: Aug 20, 2025

Brain Morphology of Cannabis Users With or Without Psychosis: A Pilot MRI Study
07:30

Brain Morphology of Cannabis Users With or Without Psychosis: A Pilot MRI Study

Published on: August 18, 2020

6.8K

Cannabis and Psychosis.

Michelle L West1, Shadi Sharif1

  • 1Department of Psychiatry, University of Colorado School of Medicine, Anschutz Health Sciences Building, 1890 N Revere Court, Mailstop F443, Aurora, CO 80045, USA.

Child and Adolescent Psychiatric Clinics of North America
|November 21, 2022
PubMed
Summary

Cannabis use in young people is linked to increased psychosis risk and symptom worsening. More clinical trials are needed to develop effective treatments for co-occurring psychosis and cannabis use disorders.

Keywords:
AdolescentCannabisClinical high riskEarly interventionEarly psychosisFirst-episode psychosisPsychosisYouth

More Related Videos

Administration of Δ9-Tetrahydrocannabinol (THC) in Adolescent and Adult Mice
07:51

Administration of Δ9-Tetrahydrocannabinol (THC) in Adolescent and Adult Mice

Published on: August 1, 2025

122
Development of a Preclinical Inhalation Model to Test Vaporized Cannabis Distillates
06:09

Development of a Preclinical Inhalation Model to Test Vaporized Cannabis Distillates

Published on: May 30, 2025

258

Related Experiment Videos

Last Updated: Aug 20, 2025

Brain Morphology of Cannabis Users With or Without Psychosis: A Pilot MRI Study
07:30

Brain Morphology of Cannabis Users With or Without Psychosis: A Pilot MRI Study

Published on: August 18, 2020

6.8K
Administration of Δ9-Tetrahydrocannabinol (THC) in Adolescent and Adult Mice
07:51

Administration of Δ9-Tetrahydrocannabinol (THC) in Adolescent and Adult Mice

Published on: August 1, 2025

122
Development of a Preclinical Inhalation Model to Test Vaporized Cannabis Distillates
06:09

Development of a Preclinical Inhalation Model to Test Vaporized Cannabis Distillates

Published on: May 30, 2025

258

Area of Science:

  • Psychiatry
  • Addiction Medicine
  • Developmental Psychology

Background:

  • Cannabis use is prevalent among young people.
  • Cannabis use is associated with an increased risk of psychotic symptoms.
  • Cannabis use may worsen existing psychosis in vulnerable youth.

Purpose of the Study:

  • To review the relationship between psychosis and cannabis use in young people.
  • To identify gaps in clinical research for treating co-occurring psychosis and cannabis use.

Main Methods:

  • Literature review of existing research on psychosis and cannabis use in adolescents and young adults.
  • Analysis of studies examining the impact of cannabis on psychotic symptom development and exacerbation.
  • Examination of current treatment approaches and their limitations.

Main Results:

  • Cannabis use is linked to both subthreshold and acute psychotic symptoms in youth.
  • Cannabis use can exacerbate psychosis in individuals with pre-existing risk or diagnosed psychotic disorders.
  • Existing treatment guidelines for early psychosis care suggest incorporating cannabis use assessment but lack robust clinical trial data.

Conclusions:

  • There is a significant overlap between psychosis and cannabis use in young people.
  • Evidence-based treatments for co-occurring psychosis and cannabis use in youth are lacking due to insufficient clinical trial research.
  • Further research is crucial to develop and validate effective interventions for this population.